Home » MONITORING BOARD RECOMMENDS CONTINUATION OF MYVAX TRIAL
MONITORING BOARD RECOMMENDS CONTINUATION OF MYVAX TRIAL
July 29, 2005
Genitope announced that its independent data safety monitoring board reviewed the first planned interim analysis of data for efficacy in its pivotal Phase III clinical trial for treatment of follicular non-Hodgkin's Lymphoma (fNHL) and recommended that the trial continue as planned. The next interim analysis of data for efficacy is scheduled to occur in mid-2006.
This trial is evaluating the safety and efficacy of the company's lead product candidate, MyVax Personalized Immunotherapy, in patients with previously untreated fNHL. The trial compares patients treated with MyVax to patients treated with a nonspecific immunotherapy control.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct